In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment

Malgorzata Wasniewska, Filippo De Luca, Alessandra Cassio, Nicola Oggiaro, Paola Gianino, Maurizio Delvecchio, Rosalba Aiazzi, Vera Stoppioni, Fortunato Lombardo, Maria Francesca Messina, Mariella Valenzise, Teresa Arrigo

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective: To evaluate in a cohort of infants with congenital hypothyroidism (CH): (a) the frequency of bone maturation (BM) retardation at birth and (b) whether BM delay at birth may be considered as a tool to make a prognosis of psychomotor status at the age of 1 year, irrespective of other variables related to treatment. Design: BM at birth, CH severity and developmental quotient (DQ) at the age of 1 year were retrospectively evaluated in 192 CH infants selected by the following inclusion criteria: (a) gestation age ranging between 38 and 42 weeks; (b) onset of therapy within the first month of life; (c) initial thyroxine (L-T4) dosage ranging from 10 to 12 μg/kg/day; (d) normalization of serum thyrotropin (TSH) levels before the age of 3 months; (e) monthly adjustments of L-T4 dose during the first year of life with serum TSH levels ranging from 0.5 to 4 mIU/l; (f) no major diseases and/or physical handicaps associated with CH; (g) availability of both thyroid scanning and knee X-rays at the time of treatment initiation; (h) availability of DQ assessment at an average age of 12 months. Methods: BM was considered normal if the distal femur bony nucleus diameter exceeded 3 mm (group A) or retarded if either this nucleus was absent (subgroup B1) or its diameter was <3 mm (subgroup B2). DQ was evaluated with the Brunet-Lézine test. Results: In 44.3 % of cases BM was either delayed (23.5%) or severely delayed (20.8%). The risk of BM retardation was higher in the patients with athyreosis than in the remaining patients (41/57 vs 44/135, X2 = 25.13, P <0.005). BM-retarded infants showed a more severe biochemical picture of CH at birth and a lower DQ at the age of one year compared with the group A patients. If compared with infants of subgroup B2 those of subgroup B1 exhibited significantly lower T4 levels at birth and a more frequent association with athyreosis (70.0 vs 30.0%; X2 = 7.49, P <0.01), whereas DQ was superimposable in both subgroups. Conclusions: (a) BM at birth is delayed in almost half of CH patients and (b) CH severity per se can affect DQ at the age of 1 year irrespective of other variables related to therapy.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalEuropean Journal of Endocrinology
Volume149
Issue number1
Publication statusPublished - Jul 1 2003

Fingerprint

Congenital Hypothyroidism
Parturition
Bone and Bones
Therapeutics
Thyrotropin
Serum
Thyroxine
Femur
Knee
Thyroid Gland
X-Rays
Pregnancy

ASJC Scopus subject areas

  • Endocrinology

Cite this

In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment. / Wasniewska, Malgorzata; De Luca, Filippo; Cassio, Alessandra; Oggiaro, Nicola; Gianino, Paola; Delvecchio, Maurizio; Aiazzi, Rosalba; Stoppioni, Vera; Lombardo, Fortunato; Messina, Maria Francesca; Valenzise, Mariella; Arrigo, Teresa.

In: European Journal of Endocrinology, Vol. 149, No. 1, 01.07.2003, p. 1-6.

Research output: Contribution to journalArticle

Wasniewska, M, De Luca, F, Cassio, A, Oggiaro, N, Gianino, P, Delvecchio, M, Aiazzi, R, Stoppioni, V, Lombardo, F, Messina, MF, Valenzise, M & Arrigo, T 2003, 'In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment', European Journal of Endocrinology, vol. 149, no. 1, pp. 1-6.
Wasniewska, Malgorzata ; De Luca, Filippo ; Cassio, Alessandra ; Oggiaro, Nicola ; Gianino, Paola ; Delvecchio, Maurizio ; Aiazzi, Rosalba ; Stoppioni, Vera ; Lombardo, Fortunato ; Messina, Maria Francesca ; Valenzise, Mariella ; Arrigo, Teresa. / In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment. In: European Journal of Endocrinology. 2003 ; Vol. 149, No. 1. pp. 1-6.
@article{0c8f10815c074c139fbeab1cd0fa9704,
title = "In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment",
abstract = "Objective: To evaluate in a cohort of infants with congenital hypothyroidism (CH): (a) the frequency of bone maturation (BM) retardation at birth and (b) whether BM delay at birth may be considered as a tool to make a prognosis of psychomotor status at the age of 1 year, irrespective of other variables related to treatment. Design: BM at birth, CH severity and developmental quotient (DQ) at the age of 1 year were retrospectively evaluated in 192 CH infants selected by the following inclusion criteria: (a) gestation age ranging between 38 and 42 weeks; (b) onset of therapy within the first month of life; (c) initial thyroxine (L-T4) dosage ranging from 10 to 12 μg/kg/day; (d) normalization of serum thyrotropin (TSH) levels before the age of 3 months; (e) monthly adjustments of L-T4 dose during the first year of life with serum TSH levels ranging from 0.5 to 4 mIU/l; (f) no major diseases and/or physical handicaps associated with CH; (g) availability of both thyroid scanning and knee X-rays at the time of treatment initiation; (h) availability of DQ assessment at an average age of 12 months. Methods: BM was considered normal if the distal femur bony nucleus diameter exceeded 3 mm (group A) or retarded if either this nucleus was absent (subgroup B1) or its diameter was <3 mm (subgroup B2). DQ was evaluated with the Brunet-L{\'e}zine test. Results: In 44.3 {\%} of cases BM was either delayed (23.5{\%}) or severely delayed (20.8{\%}). The risk of BM retardation was higher in the patients with athyreosis than in the remaining patients (41/57 vs 44/135, X2 = 25.13, P <0.005). BM-retarded infants showed a more severe biochemical picture of CH at birth and a lower DQ at the age of one year compared with the group A patients. If compared with infants of subgroup B2 those of subgroup B1 exhibited significantly lower T4 levels at birth and a more frequent association with athyreosis (70.0 vs 30.0{\%}; X2 = 7.49, P <0.01), whereas DQ was superimposable in both subgroups. Conclusions: (a) BM at birth is delayed in almost half of CH patients and (b) CH severity per se can affect DQ at the age of 1 year irrespective of other variables related to therapy.",
author = "Malgorzata Wasniewska and {De Luca}, Filippo and Alessandra Cassio and Nicola Oggiaro and Paola Gianino and Maurizio Delvecchio and Rosalba Aiazzi and Vera Stoppioni and Fortunato Lombardo and Messina, {Maria Francesca} and Mariella Valenzise and Teresa Arrigo",
year = "2003",
month = "7",
day = "1",
language = "English",
volume = "149",
pages = "1--6",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - In congenital hypothyroidism bone maturation at birth may be a predictive factor of psychomotor development during the first year of life irrespective of other variables related to treatment

AU - Wasniewska, Malgorzata

AU - De Luca, Filippo

AU - Cassio, Alessandra

AU - Oggiaro, Nicola

AU - Gianino, Paola

AU - Delvecchio, Maurizio

AU - Aiazzi, Rosalba

AU - Stoppioni, Vera

AU - Lombardo, Fortunato

AU - Messina, Maria Francesca

AU - Valenzise, Mariella

AU - Arrigo, Teresa

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Objective: To evaluate in a cohort of infants with congenital hypothyroidism (CH): (a) the frequency of bone maturation (BM) retardation at birth and (b) whether BM delay at birth may be considered as a tool to make a prognosis of psychomotor status at the age of 1 year, irrespective of other variables related to treatment. Design: BM at birth, CH severity and developmental quotient (DQ) at the age of 1 year were retrospectively evaluated in 192 CH infants selected by the following inclusion criteria: (a) gestation age ranging between 38 and 42 weeks; (b) onset of therapy within the first month of life; (c) initial thyroxine (L-T4) dosage ranging from 10 to 12 μg/kg/day; (d) normalization of serum thyrotropin (TSH) levels before the age of 3 months; (e) monthly adjustments of L-T4 dose during the first year of life with serum TSH levels ranging from 0.5 to 4 mIU/l; (f) no major diseases and/or physical handicaps associated with CH; (g) availability of both thyroid scanning and knee X-rays at the time of treatment initiation; (h) availability of DQ assessment at an average age of 12 months. Methods: BM was considered normal if the distal femur bony nucleus diameter exceeded 3 mm (group A) or retarded if either this nucleus was absent (subgroup B1) or its diameter was <3 mm (subgroup B2). DQ was evaluated with the Brunet-Lézine test. Results: In 44.3 % of cases BM was either delayed (23.5%) or severely delayed (20.8%). The risk of BM retardation was higher in the patients with athyreosis than in the remaining patients (41/57 vs 44/135, X2 = 25.13, P <0.005). BM-retarded infants showed a more severe biochemical picture of CH at birth and a lower DQ at the age of one year compared with the group A patients. If compared with infants of subgroup B2 those of subgroup B1 exhibited significantly lower T4 levels at birth and a more frequent association with athyreosis (70.0 vs 30.0%; X2 = 7.49, P <0.01), whereas DQ was superimposable in both subgroups. Conclusions: (a) BM at birth is delayed in almost half of CH patients and (b) CH severity per se can affect DQ at the age of 1 year irrespective of other variables related to therapy.

AB - Objective: To evaluate in a cohort of infants with congenital hypothyroidism (CH): (a) the frequency of bone maturation (BM) retardation at birth and (b) whether BM delay at birth may be considered as a tool to make a prognosis of psychomotor status at the age of 1 year, irrespective of other variables related to treatment. Design: BM at birth, CH severity and developmental quotient (DQ) at the age of 1 year were retrospectively evaluated in 192 CH infants selected by the following inclusion criteria: (a) gestation age ranging between 38 and 42 weeks; (b) onset of therapy within the first month of life; (c) initial thyroxine (L-T4) dosage ranging from 10 to 12 μg/kg/day; (d) normalization of serum thyrotropin (TSH) levels before the age of 3 months; (e) monthly adjustments of L-T4 dose during the first year of life with serum TSH levels ranging from 0.5 to 4 mIU/l; (f) no major diseases and/or physical handicaps associated with CH; (g) availability of both thyroid scanning and knee X-rays at the time of treatment initiation; (h) availability of DQ assessment at an average age of 12 months. Methods: BM was considered normal if the distal femur bony nucleus diameter exceeded 3 mm (group A) or retarded if either this nucleus was absent (subgroup B1) or its diameter was <3 mm (subgroup B2). DQ was evaluated with the Brunet-Lézine test. Results: In 44.3 % of cases BM was either delayed (23.5%) or severely delayed (20.8%). The risk of BM retardation was higher in the patients with athyreosis than in the remaining patients (41/57 vs 44/135, X2 = 25.13, P <0.005). BM-retarded infants showed a more severe biochemical picture of CH at birth and a lower DQ at the age of one year compared with the group A patients. If compared with infants of subgroup B2 those of subgroup B1 exhibited significantly lower T4 levels at birth and a more frequent association with athyreosis (70.0 vs 30.0%; X2 = 7.49, P <0.01), whereas DQ was superimposable in both subgroups. Conclusions: (a) BM at birth is delayed in almost half of CH patients and (b) CH severity per se can affect DQ at the age of 1 year irrespective of other variables related to therapy.

UR - http://www.scopus.com/inward/record.url?scp=0038825624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038825624&partnerID=8YFLogxK

M3 - Article

C2 - 12824859

AN - SCOPUS:0038825624

VL - 149

SP - 1

EP - 6

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 1

ER -